Đánh giá ban đầu điều trị ung thư vú tái phát di căn có thụ thể nội tiết dương tính HER-2 âm tính bằng fulvestrant tại Bệnh viện Đa khoa Đồng Nai=Initial evaluation of the treatment effectiveness of fulvestrant in recurrent or metastasis breast cancer with HR(+), HER2(-) at Dong Nai General Hospital

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Đức Nhân Lê, Văn Hòa Ngô

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.225-232

Bộ sưu tập: Metadata

ID: 246443

Thêm vào giỏ

Bệnh nhân ung thư vú di căn hoặc tái phát, di căn có thụ thể nội tiết dương tính, Her-2 âm tính được điều trị nội tiết bằng fulvestrant từ tháng 1 năm 2021 đến tháng 10 năm 2023 tại Bệnh viện đa khoa Đồng Nai. Mục tiêu: Đánh giá ban đầu điều trị ung thư vú di căn hoặc tái phát di căn có thụ thể nội tiết dương tính Her-2 âm tính bằng fulvestrant. Kết quả: Thời gian điều trị trung bình 7,1 tháng. Bệnh nhân điều trị ít nhất 3 tháng, dài nhất là 25 tháng. Bệnh ổn định đạt tỷ lệ cao nhất 60%. Có 2 bệnh tiến triển trong quá trình điều trị, một bệnh nhân tử vong do suy gan cấp. Không có bệnh đáp ứng hoàn toàn. 3/15 bệnh nhân đáp ứng một phần. Thời gian sống thêm không bệnh tiến triển của nhóm bệnh nghiên cứu của chúng tôi là 7 ± 1,54 tháng. Kết luận: Fulvestrant là thuốc nội tiết có hiệu quả, nên cân nhắc điều trị sớm ở bệnh nhân ung thư vú tái phát di căn, thụ thể nội tiết dương tính, gánh nặng khối u không lớn, điều trị bước đầu hiệu quả sẽ cao hơn các bước điều trị tiếp theo.Patients with metastatic or recurrent metastatic breast cancer with hormone receptor-positive, receiving endocrine therapy with fulvestrant from January 2021 to October 2023 at Dong Nai General Hospital. Purpose: Results of initial treatment of metastatic or recurrent metastatic breast cancer that is hormone receptor-positive and Her2- negative with fulvestrant. Results: The average treatment time is 7.1 months. Patients are treated for at least 3 months, the longest is 25 months. Stable disease reaching the highest rate of 60%. There were 2 disease progression during treatment, one patient died due to acute liver failure. No case complete response. 3/15 patients partially respond. The progression-free survival time of our study group is 7 ± 1.54 months. Conclusions: Fulvestrant is an effective endocrine drug, early treatment should be considered in patients with breast cancer with metastatic recurrence, positive hormone receptors, low tumor burden. First-line treatment will be more effective than subsequent treatment steps.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR